NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals
Novavax is scheduled to release its second-quarter 2026 financial results before the U.S. market opens on Thursday. Novavax has moved away from trying to sell COVID vaccines on a large scale by itself. Instead, it is running a leaner operation that mainly licenses its proprietary Matrix-M adjuvant to larger drugmakers. Certain retail investors on Stocktwits … Read more